Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1849 1
1864 1
1865 2
1866 2
1867 1
1868 1
1873 1
1881 1
1893 1
1910 1
1914 1
1916 3
1917 1
1918 2
1919 3
1922 1
1923 1
1926 1
1927 3
1928 1
1929 1
1930 2
1932 1
1933 2
1936 4
1937 1
1938 1
1939 4
1940 2
1941 2
1943 1
1944 16
1945 48
1946 208
1947 131
1948 112
1949 80
1950 150
1951 232
1952 271
1953 304
1954 333
1955 350
1956 309
1957 325
1958 329
1959 199
1960 41
1961 60
1962 37
1963 477
1964 713
1965 916
1966 1169
1967 1255
1968 1376
1969 1422
1970 1463
1971 1590
1972 1687
1973 1899
1974 2115
1975 9237
1976 8999
1977 9078
1978 9508
1979 9746
1980 13338
1981 18656
1982 20512
1983 23718
1984 26019
1985 26585
1986 28573
1987 30716
1988 32599
1989 35543
1990 37934
1991 39709
1992 41189
1993 43091
1994 45540
1995 47249
1996 49258
1997 52757
1998 56021
1999 59836
2000 64719
2001 68968
2002 74465
2003 82961
2004 89900
2005 97518
2006 98981
2007 107305
2008 116907
2009 127743
2010 142795
2011 159318
2012 174075
2013 188883
2014 199729
2015 205539
2016 124676
2017 86690
2018 143677
2019 152645
2020 170344
2021 178728
2022 164129
2023 132890
2024 24721

Text availability

Article attribute

Article type

Publication date

Search Results

3,577,222 results

Results by year

Filters applied: . Clear all
The following terms were not found in PubMed: most-favo, red-nation
Page 1
Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update.
Sun C, Shen L, Zhang Z, Xie X. Sun C, et al. Genes (Basel). 2020 Jul 23;11(8):837. doi: 10.3390/genes11080837. Genes (Basel). 2020. PMID: 32717791 Free PMC article. Review.
Over the last few years, there has been considerable development of diagnosis and therapeutics for DMD, but current treatments do not cure the disease. ...Furthermore, we present the clinical potential of advanced strategies combining gene editing, cell-based the …
Over the last few years, there has been considerable development of diagnosis and therapeutics for DMD, but current treatments …
Current Clinical Applications of In Vivo Gene Therapy with AAVs.
Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA, Salabarria S, Corti M, Byrne BJ, Tremblay JP. Mendell JR, et al. Mol Ther. 2021 Feb 3;29(2):464-488. doi: 10.1016/j.ymthe.2020.12.007. Epub 2020 Dec 10. Mol Ther. 2021. PMID: 33309881 Free PMC article. Review.
For more than 30 years, hundreds of researchers have maintained that genetic modifications would provide effective treatments for many inherited human diseases, offering durable and possibly curative clinical benefit with a single treatment. ...Dozens of other tr …
For more than 30 years, hundreds of researchers have maintained that genetic modifications would provide effective treatments for man …
mRNA-based cancer therapeutics.
Liu C, Shi Q, Huang X, Koo S, Kong N, Tao W. Liu C, et al. Nat Rev Cancer. 2023 Aug;23(8):526-543. doi: 10.1038/s41568-023-00586-2. Epub 2023 Jun 13. Nat Rev Cancer. 2023. PMID: 37311817 Review.
Due to the fact that mRNA technology allows the production of diverse vaccines and treatments in a shorter time frame and with reduced expense compared to conventional approaches, there has been a surge in the use of mRNA-based therapeutics in recent years. With the …
Due to the fact that mRNA technology allows the production of diverse vaccines and treatments in a shorter time frame and with reduce …
Diagnosis and management of functional neurological disorder.
Aybek S, Perez DL. Aybek S, et al. BMJ. 2022 Jan 24;376:o64. doi: 10.1136/bmj.o64. BMJ. 2022. PMID: 35074803 Review.
Twenty two studies on motor and 27 studies on seizure type symptoms report high specificities of clinical signs (64-100%), and individual signs are reviewed. Rehabilitative interventions (physical and occupational therapy) are treatments of choice for functional mot …
Twenty two studies on motor and 27 studies on seizure type symptoms report high specificities of clinical signs (64-100%), and individual si …
Neuromodulation in epilepsy: state-of-the-art approved therapies.
Ryvlin P, Rheims S, Hirsch LJ, Sokolov A, Jehi L. Ryvlin P, et al. Lancet Neurol. 2021 Dec;20(12):1038-1047. doi: 10.1016/S1474-4422(21)00300-8. Epub 2021 Oct 25. Lancet Neurol. 2021. PMID: 34710360 Review.
Biomarkers to predict response to neuromodulation therapies are not available, and high-level evidence to aid decision making about when and for whom these therapies should be preferred over other antiepileptic treatments is scant. Future studies are thus needed to address …
Biomarkers to predict response to neuromodulation therapies are not available, and high-level evidence to aid decision making about when and …
Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments.
Zobdeh F, Ben Kraiem A, Attwood MM, Chubarev VN, Tarasov VV, Schiöth HB, Mwinyi J. Zobdeh F, et al. Br J Pharmacol. 2021 Dec;178(23):4588-4607. doi: 10.1111/bph.15657. Epub 2021 Sep 26. Br J Pharmacol. 2021. PMID: 34379793 Free article. Review.
Migraine is the sixth most prevalent disease globally, a major cause of disability, and it imposes an enormous personal and socio-economic burden. Migraine treatment is often limited by insufficient therapy response, leading to the need for individually adjusted …
Migraine is the sixth most prevalent disease globally, a major cause of disability, and it imposes an enormous personal and socio-economic b …
Brain stimulation treatment for bipolar disorder.
Mutz J. Mutz J. Bipolar Disord. 2023 Feb;25(1):9-24. doi: 10.1111/bdi.13283. Epub 2022 Dec 21. Bipolar Disord. 2023. PMID: 36515461 Free PMC article. Review.
AIMS: Bipolar disorders are clinically complex, chronic and recurrent disorders. Few treatment options are effective across hypomanic, manic, depressive and mixed states and as continuation or maintenance treatment after initial symptom remission. ...CONCLUSION: Whi …
AIMS: Bipolar disorders are clinically complex, chronic and recurrent disorders. Few treatment options are effective across hypomanic …
Enhancing cancer immunotherapy with nanomedicine.
Irvine DJ, Dane EL. Irvine DJ, et al. Nat Rev Immunol. 2020 May;20(5):321-334. doi: 10.1038/s41577-019-0269-6. Epub 2020 Jan 31. Nat Rev Immunol. 2020. PMID: 32005979 Free PMC article. Review.
Therapeutic targeting of the immune system in cancer is now a clinical reality and marked successes have been achieved, most notably through the use of checkpoint blockade antibodies and chimeric antigen receptor T cell therapy. However, efforts to develop new immunotherap …
Therapeutic targeting of the immune system in cancer is now a clinical reality and marked successes have been achieved, most notably through …
Oncolytic viruses for cancer immunotherapy.
Hemminki O, Dos Santos JM, Hemminki A. Hemminki O, et al. J Hematol Oncol. 2020 Jun 29;13(1):84. doi: 10.1186/s13045-020-00922-1. J Hematol Oncol. 2020. PMID: 32600470 Free PMC article. Review.
In this review, we discuss the use of oncolytic viruses in cancer immunotherapy treatments in general, with a particular focus on adenoviruses. These serve as a model to elucidate how versatile viruses are, and how they can be used to complement other cancer therapies to g …
In this review, we discuss the use of oncolytic viruses in cancer immunotherapy treatments in general, with a particular focus on ade …
Diabetes Mellitus and Cardiovascular Disease.
Schmidt AM. Schmidt AM. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):558-568. doi: 10.1161/ATVBAHA.119.310961. Arterioscler Thromb Vasc Biol. 2019. PMID: 30786741 Free PMC article. Review.
The advent of the CVOT (Cardiovascular Outcomes Trials) for new antidiabetes mellitus treatments has uncovered unexpected benefits of cardiovascular protection in some of the new classes of agents, such as the GLP-1 RAs (glucagon-like peptide-1 receptor agonists) and the S …
The advent of the CVOT (Cardiovascular Outcomes Trials) for new antidiabetes mellitus treatments has uncovered unexpected benefits of …
3,577,222 results
You have reached the last available page of results. Please see the User Guide for more information.